A ‘Textbook’ Recovery After Lung Cancer Surgery Predicts Who Lives Longer

When a patient with lung cancer undergoes surgery after receiving drug therapy beforehand, surgeons and oncologists have long focused on a single question: how much did the tumor shrink? A new multicenter study suggests that another, often overlooked dimension of care—the sheer smoothness of the entire surgical journey—carries powerful information about survival. The research, published in BMC Cancer, introduces evidence that achieving what surgeons call a textbook outcome after neoadjuvant therapy and lung resection is independently linked to longer overall survival, and, strikingly, to a greater likelihood that patients go on to receive the adjuvant treatments that could further improve their prognosis.

The concept of textbook outcome is deceptively simple. It is a composite quality benchmark that is satisfied only when every element of a surgical episode goes ideally: the operation achieves an R0 resection, meaning the tumor and its margins are completely removed with no residual cancer visible to the pathologist; an adequate number of lymph nodes is dissected and examined so that staging is reliable; and the perioperative period passes without significant complications, readmission, or prolonged hospitalization. If any single component fails—a positive margin, an insufficient nodal sample, an anastomotic leak, a prolonged air leak requiring reintervention—the textbook outcome is not achieved. The measure originated in surgical oncology as a way to capture quality of care in a single, patient-centered metric rather than a scatter of separate indicators, and it has since been validated in esophageal, pancreatic, colorectal, and gastric cancer surgery. Its application to non-small cell lung cancer treated with neoadjuvant therapy, however, had remained underexplored until now.

The study team, led by researchers at Fujian Medical University Union Hospital together with collaborators at six tertiary hospitals across Fujian Province, China, retrospectively analyzed 347 patients with non-small cell lung cancer who underwent curative-intent resection between 2015 and 2022 after receiving neoadjuvant therapy. Neoadjuvant treatment—chemotherapy, immunotherapy, or chemoradiotherapy delivered before surgery—has become a cornerstone for locally advanced disease, increasingly incorporating immune checkpoint inhibitors that target the PD-1 and PD-L1 pathways. But the preoperative drugs add complexity: they can alter tissue planes, inflame the operative field, and influence both pathological response and surgical difficulty. The researchers asked whether the composite textbook outcome measure could cut through this complexity and deliver prognostic information that conventional measures miss.

The headline finding was that 278 of the 347 patients, or 80.1 percent, achieved a textbook outcome. That figure is itself informative: even in experienced tertiary centers, roughly one in five patients treated with neoadjuvant therapy before lung resection experienced at least one deviation from the ideal surgical pathway. Using logistic regression, the team identified two independent predictors of failure. The first was a Charlson comorbidity index of 3 or higher, a weighted score that quantifies a patient’s burden of pre-existing conditions such as severe cardiac disease, chronic pulmonary disease, diabetes with end-organ damage, or renal impairment. The second was ypN-positive disease—evidence that cancer had persisted in the regional lymph nodes despite the preoperative treatment. Both factors make intuitive sense. Patients with multiple comorbidities have less physiological reserve to weather surgical stress, while residual nodal disease often reflects more aggressive biology and more extensive, technically demanding dissections.

The survival analysis yielded the study’s most consequential result. After multivariable adjustment for competing risk factors, failure to achieve a textbook outcome was independently associated with shorter overall survival, with a hazard ratio of 1.61 and a 95 percent confidence interval of 1.02 to 2.52, reaching statistical significance at P equal to 0.039. In practical terms, patients whose surgical course deviated from the textbook ideal faced roughly a 60 percent higher hazard of death during follow-up compared with those who achieved it. The association with disease-free survival, by contrast, did not reach statistical significance, with a hazard ratio of 1.33 and a confidence interval spanning 0.88 to 2.01 at P equal to 0.180. The authors interpret this asymmetry carefully: the composite metric appears to capture not only oncological completeness but also the physiological toll of a complicated recovery, which may weigh more heavily on long-term overall survival than on the timing of cancer recurrence alone.

Perhaps the most clinically provocative finding concerned adjuvant therapy delivery. Postoperative treatment—additional chemotherapy, radiation, or immunotherapy given after recovery from surgery—is a critical lever for improving outcomes in patients at high risk of recurrence. Yet the study found that patients who achieved a textbook outcome were far more likely to receive adjuvant therapy than those who did not: 72.3 percent versus 46.4 percent, a difference that was highly significant. Even after statistical adjustment, failure to achieve a textbook outcome remained strongly associated with a lower likelihood of receiving adjuvant treatment, with an odds ratio of 0.28. This creates what the researchers describe as a concerning cascade: the very patients whose complicated recoveries signal higher risk are also the patients most likely to fall through the cracks of postoperative treatment, whether because of prolonged convalescence, clinician hesitancy, patient frailty, or logistical barriers that compound one another.

The study also tackled a question at the frontier of thoracic oncology: how the textbook outcome measure relates to major pathological response, or MPR. MPR is defined as the presence of 10 percent or fewer viable tumor cells in the resected specimen and has emerged as a leading surrogate endpoint in trials of neoadjuvant immunotherapy, because it reflects how completely the preoperative drugs eradicated the cancer. But MPR says nothing about the surgery itself or the recovery. The researchers therefore constructed a combined stratification that crossed MPR status with textbook outcome status. The analysis revealed distinct prognostic groups—patients who achieved both fared best, while discordant groups occupied intermediate positions—demonstrating that pathological response and perioperative recovery carry complementary, non-overlapping information.

The statistical evidence for that complementarity was formalized through model-fit testing. Adding textbook outcome to a prognostic model built on MPR alone significantly improved the fit for both overall survival and disease-free survival, with P values of 0.004 and 0.029 respectively, as assessed by likelihood-based criteria including the Akaike information criterion. In plain language, a model that knows only how the tumor responded to drugs is measurably less informative than one that also knows whether the operation and recovery proceeded without incident. This argues for a two-axis approach to postoperative risk assessment: one axis describing the biology of the residual disease, the other describing the quality and consequences of the surgical episode itself.

The implications for clinical practice are tangible. First, textbook outcome could serve as a practical quality-improvement target for thoracic surgery programs, since its component criteria—R0 resection, adequate nodal dissection, uncomplicated recovery—are auditable in routine records. Second, the strong link between failing to achieve the composite endpoint and reduced adjuvant therapy delivery suggests a concrete intervention point: patients who experience perioperative complications or incomplete resections should be flagged for dedicated follow-up to ensure that adjuvant treatment decisions are actively revisited once they recover, rather than quietly abandoned. Third, the combined MPR–textbook outcome framework offers a more nuanced postoperative risk stratification tool that could guide trial design and, eventually, individualized surveillance intensity.

The authors and commentators alike caution that the retrospective design imposes limits. The cohort was drawn from six tertiary hospitals in a single Chinese province, and patterns of perioperative care, adjuvant treatment selection, and follow-up may differ elsewhere. Retrospective analyses are also vulnerable to residual confounding: unmeasured factors—tumor molecular characteristics, specific neoadjuvant regimens, surgeon volume, patient preferences—could influence both the likelihood of a textbook outcome and survival. The authors note that the study was approved by the Institutional Ethics Review Board of Fujian Medical University Union Hospital and conducted under the Declaration of Helsinki, with informed consent waived for the anonymized retrospective data. Prospective validation in diverse populations, and ideally in the context of ongoing immunotherapy-era trials, will be needed before textbook outcome becomes a standard element of postoperative decision-making in lung cancer. Still, the study makes a compelling case that the road to better lung cancer outcomes runs not only through shrinking tumors before surgery, but through ensuring that the operation and its aftermath unfold exactly as the textbook says they should.

Subject of Research: Prognostic value of textbook outcome in resected non-small cell lung cancer after neoadjuvant therapy

Article Title: Prognostic value of textbook outcome in resected non-small cell lung cancer after neoadjuvant therapy: a multicenter retrospective study

Article References: Prognostic value of textbook outcome in resected non-small cell lung cancer after neoadjuvant therapy: a multicenter retrospective study. (n.d.). https://doi.org/10.1186/s12885-026-17131-7

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17131-7

Keywords: non-small cell lung cancer, textbook outcome, neoadjuvant therapy, major pathological response, adjuvant therapy, overall survival, disease-free survival, R0 resection, lymph node dissection, perioperative complications, prognosis, thoracic surgery